Malignant Tumors of Major Salivary Gland Origin: A Matched-Pair Analysis of the Role of Combined Surgery and Postoperative Radiotherapy

1990 ◽  
Vol 116 (3) ◽  
pp. 290-293 ◽  
Author(s):  
J. G. Armstrong ◽  
L. B. Harrison ◽  
R. H. Spiro ◽  
D. E. Fass ◽  
E. W. Strong ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Malignant Tumors ◽  
Postoperative Radiotherapy ◽  
Matched Pair ◽  
Major Salivary Gland ◽  
Combined Surgery ◽  
Matched Pair Analysis ◽  
Pair Analysis

scholarly journals Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease

2020 ◽  
Author(s):  
Alexander Rühle ◽  
Sofie Rothhaar ◽  
Erik Haehl ◽  
Tobias Kalckreuth ◽  
Tanja Sprave ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Matched Pair ◽  
Salivary Gland Cancer ◽  
Younger Patients ◽  
Matched Pair Analysis ◽  
Salivary Gland Carcinomas ◽  
Comorbidity Burden ◽  
Pair Analysis

Abstract Purpose This study analyzed survival and toxicity after (chemo)radiotherapy for primary salivary gland cancer patients aged ≥ 65 years and compared these results with younger patients using a matched-pair analysis. Methods Twenty-nine elderly patients with primary salivary gland carcinomas treated with (chemo)radiotherapy from 2008 to 2020 at University of Freiburg Medical Center were analyzed for oncological outcomes and therapy-associated toxicities. Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method, and the influence of clinical parameters on patient outcomes was assessed. A matched-pair analysis was performed after matching with patients < 65 years. Results Nine patients (31.0%) received definitive (chemo)radiotherapy, and 20 patients (69.0%) were treated in the adjuvant setting. 2-year LRC, PFS and OS ranged at 82.4%, 53.7% and 71.8%, respectively. Smoking (HR 3.980, p = 0.020), reduced performance status (HR 3.735, p = 0.016) and higher comorbidity burden (HR 4.601, p = 0.005) correlated with inferior OS. Using a matched-pair analysis with younger patients, elderly patients exhibited a trend towards reduced OS (HR 3.015, p = 0.065), but not PFS (HR 1.474, p = 0.371) or LRC (HR 1.324, p = 0.633). Acute and chronic grade 3 toxicities occurred in 31.0% and 12.5% of elderly patients, respectively, and the matched-pair analysis revealed no significant differences between age groups regarding treatment-related toxicities. Conclusion Treatment-related toxicities as well as LRC and PFS were comparable for salivary gland cancer patients undergoing radiotherapy. Therefore, concerns for more pronounced toxicities or reduced local/locoregional response rates should not guide treatment decisions in affected elderly patients.

The Role of Radiotherapy in the Treatment of Malignant Tumors of the Salivary Glands

1980 ◽  
Vol 66 (4) ◽  
pp. 467-474 ◽  
Author(s):  
Marian Reinfuss ◽  
Stanislaw Korzeniowski
Keyword(s):  
Salivary Gland ◽  
Radical Surgery ◽  
Malignant Tumors ◽  
Postoperative Radiotherapy ◽  
Clinical Stage ◽  
Distant Metastases ◽  
Treatment Results ◽  
High Incidence

Treatment results in a group of 70 patients with salivary gland tumors were analyzed. Prognosis appeared to correlate with both clinical stage and malignancy of tumors. In patients irradiated postoperatively because of nonradical operation, a higher 5-year survival rate was achieved than in patients after radical surgery. It is suggested that postoperative radiotherapy improves treatment results in patients with T2 and T3 lesions. In unresectable cases (T4) a 13 % 5-year survival was achieved. In patients with highly malignant cancers a high incidence (41.9 %) of distant metastases was observed during the 5-year follow-up.

scholarly journals EMOTIONAL BURDEN IN PARENTS OF CHILDREN WITH TRISOMY 21. DESCRIPTIVE STUDY IN A COLOMBIAN POPULATION

2016 ◽  
Vol 15 (1) ◽  
Author(s):  
Sonia Jaramillo ◽  
Socorro Moreno ◽  
Viviana Rodríguez
Keyword(s):  
Emotional Exhaustion ◽  
Maslach Burnout Inventory ◽  
Descriptive Study ◽  
Matched Pair ◽  
Controlled Study ◽  
Children With Down Syndrome ◽  
Matched Pair Analysis ◽  
Depressed Mothers ◽  
Pair Analysis

The role of a parent with a disabled child can be highly demanding. There are few publications concerning parental emotional exhaustion in Latin America. The present prevalent case-controlled study evaluated the frequency of emotional exhaustion in 103 parental couples of parents of children with Down Syndrome (DS); likewise the study explores the rate of emotionally exhausted and depressed mothers in comparison with the fathers. This outcome was measured using a modified and validated version of the Maslach Burnout Inventory. The results showed a prevalence of emotional exhaustion of 52.64%. In the matched-pair analysis we found a higher chance of exhaustion in mothers in comparison with their partners.

Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate Brachytherapy

2000 ◽  
Vol 18 (6) ◽  
pp. 1187-1192 ◽  
Author(s):  
Louis Potters ◽  
Taryn Torre ◽  
Richard Ashley ◽  
Steven Leibel
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Matched Pair ◽  
Prostate Brachytherapy ◽  
Absolute Increase ◽  
Androgen Ablation ◽  
Matched Pair Analysis ◽  
Pair Analysis

PURPOSE: To assess the role of neoadjuvant androgen deprivation (NAAD) and transperineal interstitial permanent prostate brachytherapy (TIPPB) using a matched-pair analysis selected from a large cohort of patients undergoing TIPPB. PATIENTS AND METHODS: Six hundred twelve consecutive patients with clinically confined prostate cancer were treated between June 1992, and January 1997, with permanent ultrasound-guided TIPPB with either palladium-103 or iodine-125 as monotherapy or combined with external radiation. Patients with prostate glands ≥ 60 g underwent treatment with NAAD before TIPPB to reduce the prostate volume (n = 163). The median duration of NAAD was 3.4 months before TIPPB (range, 1 to 8 months). To assess the benefit of NAAD, a matched-pair analysis was performed. The American Society of Therapeutic Radiology and Oncology Consensus Group definition of prostate-specific antigen (PSA) relapse-free survival (RFS) was used with the added caveat of an absolute increase of ≥ 1.0 ng/mL. Differences in pretreatment PSA, Gleason scores, and stage were analyzed by Kaplan-Meier curves and the log-rank test. RESULTS: Two hundred sixty-three patients were matched, with a median follow-up duration of 46 months (range, 24 to 76 months). The actuarial 5-year PSA-RFS rate for all 263 patients is 86.5%. The 5-year PSA-RFS rate for patients treated with NAAD and TIPPB was 87.1% compared with 86.9% for those treated with TIPPB only (P = .935). Subgroup analysis by Gleason score groupings, pretreatment PSA, or stage of disease failed to identify any factors for which androgen ablation was beneficial. CONCLUSION: We were unable to identify any improvement with the addition of NAAD to TIPPB in patients with localized prostate cancer in this retrospective matched-pair analysis. Furthermore, there was no subset for which the addition of NAAD was found to be beneficial. Clarification of the role and duration of NAAD in patients with early-stage prostate cancer will require prospective data.

Sign in / Sign up

Export Citation Format

Share Document